Amundi Buys 17,766 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

Amundi increased its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 197.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,753 shares of the company's stock after acquiring an additional 17,766 shares during the quarter. Amundi's holdings in Schrödinger were worth $544,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV increased its holdings in shares of Schrödinger by 45.4% during the third quarter. KBC Group NV now owns 2,508 shares of the company's stock worth $47,000 after purchasing an additional 783 shares during the period. Paradigm Asset Management Co. LLC acquired a new stake in Schrödinger during the fourth quarter worth approximately $50,000. Quarry LP increased its stake in Schrödinger by 1,150.0% during the 3rd quarter. Quarry LP now owns 2,825 shares of the company's stock worth $52,000 after acquiring an additional 2,599 shares during the period. GAMMA Investing LLC increased its stake in Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company's stock worth $54,000 after acquiring an additional 1,305 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Schrödinger in the 3rd quarter valued at $102,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Schrödinger Trading Up 4.4 %

Schrödinger stock traded up $0.95 during midday trading on Monday, reaching $22.75. The company's stock had a trading volume of 833,211 shares, compared to its average volume of 745,753. The stock has a market cap of $1.66 billion, a PE ratio of -9.72 and a beta of 1.62. Schrödinger, Inc. has a 52 week low of $16.67 and a 52 week high of $29.15. The business has a 50-day moving average price of $22.92 and a 200-day moving average price of $20.77.

Remove Ads

Schrödinger (NASDAQ:SDGR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The company had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. As a group, research analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Insider Transactions at Schrödinger

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total value of $119,484.16. Following the completion of the transaction, the chief financial officer now owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.60% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on SDGR shares. Piper Sandler reduced their target price on Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. KeyCorp increased their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Schrödinger presently has a consensus rating of "Buy" and a consensus target price of $32.29.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.